Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue tetravalent vaccine, live
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dengue tetravalent vaccine, live is a live attenuated viral vaccine designed to prevent dengue disease caused by all four serotypes of the dengue virus (1, 2, 3, and 4). It works by exposing the immune system to weakened forms of these viruses so that it can mount an effective immune response upon future exposure. The primary indication is for the prevention of symptomatic and severe dengue in individuals with prior laboratory-confirmed infection living in endemic areas. There are two main products on the market: Dengvaxia (developed by Sanofi) and Qdenga (developed by Takeda). Both are approved in various regions for use in children and adolescents within specific age ranges who have had previous exposure to the virus[1][2][3][5][8].
- Brand names
- DengvaxiaQdenga
- Other names
- dengue tetravalent vaccine (live attenuated)dengue vaccine (live)
02
Targets
E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on dengue tetravalent vaccine, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue tetravalent vaccine, live.